IDPH NOTICE OF COVID-19 TREATMENT OPTIONS

Date: 11/04/22

The Illinois Department of Public Health (IDPH) alerts all providers to statewide COVID-19 treatment options.

Currently, four treatment options for mild to moderate COVID-19 illness for non-hospitalized people are available: Paxlovid, Bebtelovimab, Remdesivir, and Molnupiravir. These options can lower the chance of progression to severe disease, hospitalization, and death.

IDPH encourages providers to assess their patients within five days of symptom onset after they have been identified as having COVID-19 to determine if they are eligible for treatment.

Prescriptions can be sent directly to our federal pharmacy partners: Walgreens, Walmart, CVS, Meijer, and several community pharmacies listed in the COVID-19 Therapeutics Locator.

Please refer to the NIH Clinical Decision Aid as a treatment guide. And note that IDPH does not manage allocations for Remdesivir, which is commercially available and cannot be requested through IDPH. Remdesivir is currently the only outpatient treatment option for children under 12.

Additional Information

• For the most up-to-date treatment guidelines, visit: NIH COVID-19 GUIDELINES  
• To locate doses of COVID-19 treatments in your area, visit: the IDPH Outpatient Therapy locator
• The IDPH Therapy Matchmaker can be used if a limited number of doses is needed
• All therapeutics orders are submitted in HPoP
• Existing providers must access their accounts to create an order
• New therapeutics providers, please submit a New Provider Site Registration Form

Please contact IDPH at dph.mabtherapy@illinois.gov or call 800-889-3931 with questions.